194 related articles for article (PubMed ID: 10428922)
21. Treatment of murine candidiasis and cryptococcosis with amphotericin B incorporated into egg lecithin-bile salt mixed micelles.
Brajtburg J; Elberg S; Travis SJ; Kobayashi GS
Antimicrob Agents Chemother; 1994 Feb; 38(2):294-9. PubMed ID: 8192455
[TBL] [Abstract][Full Text] [Related]
22. Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B.
Oda MN; Hargreaves PL; Beckstead JA; Redmond KA; van Antwerpen R; Ryan RO
J Lipid Res; 2006 Feb; 47(2):260-7. PubMed ID: 16314670
[TBL] [Abstract][Full Text] [Related]
23. In-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery system.
Tabosa Do Egito ES; Appel M; Fessi H; Barratt G; Puisieux F; Devissaguet JP
J Antimicrob Chemother; 1996 Sep; 38(3):485-97. PubMed ID: 8889723
[TBL] [Abstract][Full Text] [Related]
24. Identification of Off-Patent Drugs That Show Synergism with Amphotericin B or That Present Antifungal Action against Cryptococcus neoformans and
Rossi SA; de Oliveira HC; Agreda-Mellon D; Lucio J; Mendes-Giannini MJS; García-Cambero JP; Zaragoza O
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988099
[TBL] [Abstract][Full Text] [Related]
25. Comparative in vitro antifungal susceptibility activity of amphotericin B versus amphotericin B methyl ester against Candida albicans ocular isolates.
Thanathanee O; Miller D; Ringel DM; Schaffner CP; Alfonso EC; O'Brien TP
J Ocul Pharmacol Ther; 2012 Dec; 28(6):589-92. PubMed ID: 22788845
[TBL] [Abstract][Full Text] [Related]
26. Assessment of in vitro antifungal efficacy and in vivo toxicity of Amphotericin B-loaded PLGA and PLGA-PEG blend nanoparticles.
Moraes Moreira Carraro TC; Altmeyer C; Maissar Khalil N; Mara Mainardes R
J Mycol Med; 2017 Dec; 27(4):519-529. PubMed ID: 28797532
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ
Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826
[TBL] [Abstract][Full Text] [Related]
28. Amphotericin B-albumin conjugates: Synthesis, toxicity and anti-fungal activity.
Gurudevan S; Francis AP; Jayakrishnan A
Eur J Pharm Sci; 2018 Mar; 115():167-174. PubMed ID: 29325755
[TBL] [Abstract][Full Text] [Related]
29. Oral administration of amphotericin B nanoparticles: antifungal activity, bioavailability and toxicity in rats.
Radwan MA; AlQuadeib BT; Šiller L; Wright MC; Horrocks B
Drug Deliv; 2017 Nov; 24(1):40-50. PubMed ID: 28155565
[TBL] [Abstract][Full Text] [Related]
30. Physicochemical properties and antifungal activity of amphotericin B incorporated in cholesteryl carbonate esters.
Chuealee R; Wiedmann TS; Srichana T
J Pharm Sci; 2011 May; 100(5):1727-35. PubMed ID: 21374610
[TBL] [Abstract][Full Text] [Related]
31. High purity amphotericin B.
Cleary JD; Chapman SW; Swiatlo E; Kramer R
J Antimicrob Chemother; 2007 Dec; 60(6):1331-40. PubMed ID: 17921178
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of renal toxicity and antifungal activity of free and liposomal amphotericin B following a single intravenous dose to diabetic rats with systemic candidiasis.
Wasan KM; Conklin JS
Antimicrob Agents Chemother; 1996 Aug; 40(8):1806-10. PubMed ID: 8843285
[TBL] [Abstract][Full Text] [Related]
33. Amphotericin B Loaded Nanostructured Lipid Carriers for Parenteral Delivery: Characterization, Antifungal and In vitro Toxicity Assessment.
Nimtrakul P; Tiyaboonchai W; Lamlertthon S
Curr Drug Deliv; 2019; 16(7):645-653. PubMed ID: 31362675
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and evaluation of styrene-maleic acid copolymer conjugated amphotericin B.
Banshoya K; Kaneo Y; Tanaka T; Yamamoto S; Maeda H
Int J Pharm; 2019 Dec; 572():118719. PubMed ID: 31654700
[TBL] [Abstract][Full Text] [Related]
35. Amphotericin B loaded ethyl cellulose nanoparticles with magnified oral bioavailability for safe and effective treatment of fungal infection.
Kaur K; Kumar P; Kush P
Biomed Pharmacother; 2020 Aug; 128():110297. PubMed ID: 32480227
[TBL] [Abstract][Full Text] [Related]
36. Synthesis of a highly water-soluble derivative of amphotericin B with attenuated proinflammatory activity.
Adediran SA; Day TP; Sil D; Kimbrell MR; Warshakoon HJ; Malladi SS; David SA
Mol Pharm; 2009; 6(5):1582-90. PubMed ID: 19663403
[TBL] [Abstract][Full Text] [Related]
37. In vivo activity of a novel amphotericin B formulation with synthetic cationic bilayer fragments.
Lincopan N; Mamizuka EM; Carmona-Ribeiro AM
J Antimicrob Chemother; 2003 Sep; 52(3):412-8. PubMed ID: 12917237
[TBL] [Abstract][Full Text] [Related]
38. Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations.
Fukui H; Koike T; Nakagawa T; Saheki A; Sonoke S; Tomii Y; Seki J
Int J Pharm; 2003 Nov; 267(1-2):101-12. PubMed ID: 14602388
[TBL] [Abstract][Full Text] [Related]
39. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system.
Groll AH; Giri N; Petraitis V; Petraitiene R; Candelario M; Bacher JS; Piscitelli SC; Walsh TJ
J Infect Dis; 2000 Jul; 182(1):274-82. PubMed ID: 10882607
[TBL] [Abstract][Full Text] [Related]
40. Polysaccharide pharmacokinetics: amphotericin B arabinogalactan conjugate-a drug delivery system or a new pharmaceutical entity?
Elgart A; Farber S; Domb AJ; Polacheck I; Hoffman A
Biomacromolecules; 2010 Aug; 11(8):1972-7. PubMed ID: 20690709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
